ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Regeneron records 80% complete response rate in lymphoma trial
January 03, 2019Regeneron’s CD20xCD3 bispecific antibody has achieved an 80% complete response rate in a small trial of patients with relapsed or refractory follicular lymphoma.... -
Epizyme shuts down failing lymphoma trial as FDA imposes clinical hold
August 06, 2018Epizyme’s Q2 financial results have been derailed by the company’s decision to terminate further Phase 2 development of its lead drug tazemetostat in the treatment of relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), after an interim data -
Kite Pharma climbs on strong data showing in lymphoma trial
March 02, 2017Kite Pharma released the news on Rare Diseases Day promising top-line data from a Phase 1/2 trial of its treatment for various types of non-Hodgkin lymphoma.
Pharma Sources Insight January 2025
